for assistance call: 573-882-1134


April 2017

Conference Announcements

14th Congress Advancing Xenotransplantation Science Worldwide

6th Swine in Biomedical Research Conference

November 1, 2016

Updated Publications

October 1, 2016

Publication release

Suggested Guidelines for Tissue Collection

August 1, 2016

Publication release

Birth of potential new model: PAH KO
Donation of a new model: Dr. Monique Lorson, MU donates SMN -/+ animals

February 2016

Publication release

Birth of two potential new models



October 2015

Publication release

DNA Methylation supports pig as biomedical model.

September 2015

Publication release

Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.

Zhao J, Xu W, Ross JW, Walters EM, Butler SP, Whyte JJ, Kelso L, Fatemi M, Vanderslice NC, Giroux K, Spate LD, Samuel MS, Murphy CN, Wells KD, Masiello NC, Prather RS, Velander WH. Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.

July 2015

Publication release

A Genetic Porcine Model of Cancer

L.B. Schook , T.V. Collares, W. Hu,Y. Liang, F. M. Rodrigues, L. A. Rund, K. M. Schachtschneider, F.K. Seixas, K. Singh, K.D. Wells, E. M. Walters, R.S. Prather, C.M. Counter

Targeted disruption of CD1d prevents NKT cell development in pigs

G. Yang, B. L. Artiaga, T.J. Hackmann, M.S. Samuel, E.M. Walters, S. Salek-Ardakani, J.P. Driver

February 2015

New Strains Added

The NSRRC would like to extend “Thank You” to Dr. Bob Petters from North Carolina State University for his generous donation to the NSRRC. Dr. Petters donated 19 different strains to the NSRRC to be used to study Eye disorders.

November 2014

Publication release

Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos

Whitworth KM, Lee K, Benne JA, Beaton BP, Spate LD, Murphy SL, Samuel MS, Mao J, O'Gorman C, Walters EM, Murphy CN, Driver J, Mileham A, McLaren D, Wells KD, Prather RS.

Oct 8, 2014

Press release

NSRRC accepts large donation of Transgenic Swine Eye Models.
More details to come later

May 2014

Publication release

Engraftment of human iPS and allogeneic porcine cells into pigs with inactivated RAG2 and accompanying severe combined immunodeficiency.

Kiho Lee, Deug-Nam Kwon, Toshihiko Ezashia, Yun-Jung Choi, Chankyu Park, Aaron C. Ericsson, Alana N. Brown, Melissa Samuel, Kwang-wook Park, Eric Walters, Dae Young Kim, Jae-Hwan Kim, Craig L. Franklin, Clifton N. Murphy, R. Michael Roberts, Randall S. Prather, and Jin-Hoi Kim


Archived News Links

Process for creating genetically-modified swine models made for NIH-funded Investigators by the NSRRC

Genetically-engineered animals, most notably genetically-engineered mice, have allowed scientists to make huge progress in our understanding of how cells and organisms function. Similarly, genetically-engineered swine have tremendous potential to contribute to our understanding of human disease and to address questions that cannot be answered with rodent models. However, the technology for creation of genetically-engineered swine is new and technically difficult. Because only a handful of places in the country possess this expertise, few genetically modified swine exist. As one component of the NSRRC, we will create critically needed genetically-modified swine for NIH-funded investigators.

Because of the expense and facility requirements associated with creation of new genetically-modified swine, only three new pig lines will be created per year. To determine which mutants will be made by the NSRRC, NIH-funded investigators will be asked to submit an application. The Advisory Panel will select the mutant pig lines to be made. The Advisory Panel will consider the following in selecting genetic modifications: nature of the mutation to be induced (gene addition, gene knockout/in); potential scientific value of the genetic model; potential estimates for the demand for each mutation; distinguishing characteristics that make the genetic background as well as the mutation to be introduced the most suitable; uniqueness and difficulty of the genetic modification; and knowledge of the locus into which the modification must be introduced (for a knockout/in). Since all of the mutations will be custom produced, some specialized reagents (genetic background) or information (gene sequence) may be required.

Once an application has been approved, this service will be supported by the NSRRC at no charge to the NIH-funded investigator. All genetically-modified swine created by the NSRRC will be cryopreserved. Initially, animals with a single mutation will be provided to the requesting investigator(s). Animals with homozygous mutations can also be provided, but only after sufficient time has elapsed to produce these animals in-house.